News Center
A single IVF cycle in the United States typically runs between $12,000 and $25,000 before medication, with fertility drugs adding another $3,000 to $7,000, and published figures from the CDC's national ART reporting system let you verify each clinic's outcomes before committing. The number that matters more, though, is the one no fee schedule prints: time. Two stretches of the calendar, the hormone preparation window before ovarian stimulation and the pricing of a frozen embryo transfer after a failed cycle, routinely add thousands of dollars and one to three months to treatment, and they are the reason two patients at clinics with identical sticker prices can finish treatment a year apart at very different total cost.
A standard base-cycle quote usually bundles the monitoring appointments, the egg retrieval procedure, anesthesia, laboratory fertilization, and embryo culture. Some clinics fold an initial fresh transfer into that number; many now quote it separately because elective frozen transfer has become the default at a large share of American programs. Preimplantation genetic testing, if you use it, is billed per embryo biopsied plus a flat lab fee, and it is almost never inside the base price.
The American Society for Reproductive Medicine publishes patient-facing cost guidance, and the CDC's Assisted Reproductive Technology reporting lets you look up per-cycle outcome ranges for any reporting clinic. Both are worth an hour of reading before you compare quotes, because they establish the honest baseline: wide variation between clinics is normal, and a quote that looks 30% cheaper may simply be counting fewer items.
Where published guidance and fee schedules both go quiet is timing. A quote tells you what a cycle costs. It does not tell you how many calendar weeks stand between your first blood draw and the day an embryo is transferred, and it says nothing about what happens financially if that transfer fails. Those two gaps, the pretreatment window and the second-cycle price, deserve a closer look than anything on the printed estimate.
Ovarian stimulation gets all the attention in patient forums, yet the phase before stimulation does much of the quiet work. Reproductive endocrinologists generally run a preparation window of roughly two to six weeks between the initial workup and the start of injectable medications. The length varies with your diagnosis, your cycle regularity, and what the first round of bloodwork uncovers. Patients who budget only for the stimulation phase are often surprised to learn they will pay for monitoring visits, repeat labs, and prescription during a period in which, from the outside, nothing dramatic appears to be happening.
Several tools appear in this window, and each one changes the calendar differently.
None of this is wasted time. Follicles recruited for a given retrieval cycle began their growth months earlier, and the hormonal environment they grow in during the preparation window influences how many mature eggs that cycle will yield. Skipping suppression to save three weeks can mean retrieving fewer mature oocytes, fewer embryos for testing, and a higher chance of needing a second retrieval entirely. A second retrieval costs far more than the three weeks you saved.
Build the cost honestly. The window typically carries three kinds of charges: monitoring visits with bloodwork and ultrasound (commonly a few hundred dollars each at self-pay rates), prescription costs that vary widely by pharmacy and protocol, and occasional procedures such as a saline sonogram or hysteroscopy. Add a realistic medication line, since suppression pills and priming estrogen are cheap relative to injectable gonadotropins but never free.
The larger cost is strategic. Patients flying in from abroad often book a single long trip and assume stimulation starts on arrival. If the pretreatment workup surfaces a thyroid value that needs eight weeks of adjustment, the trip produces labs and a plan rather than a retrieval. Coordinating remotely, starting suppression at home under your local physician, and flying in only for the stimulation phase is how experienced international patients handle this, and the clinics discussed later in this article all have structured remote-coordination processes for exactly that reason. Ask about it before you book flights, because the answer determines whether your first trip is two weeks or two months.
A useful rule: any clinic that promises stimulation can start within days of your first visit, without reviewing your outside records first, is compressing the one phase of treatment where compression is most likely to cost you eggs.
The first transfer fails for a substantial share of patients even with genetically normal embryos, and this is where fee structures diverge most sharply. Two clinics can quote identical base-cycle prices and still produce total treatment costs that differ by more than 100% over two attempts, purely because of how each one prices a frozen embryo transfer cycle.
The FET itself is a comparatively simple procedure: thaw an embryo, prepare the uterine lining with estrogen and progesterone, transfer. The billing behind it, though, splits into several distinct lines, and clinics bundle them differently.
| Billing Component | Bundled Into FET Fee | Billed Separately |
|---|---|---|
| Embryo thaw and survival assessment | Common | Less common |
| Lining monitoring (2–4 ultrasound and blood draws) | Varies | Frequent surprise line item |
| Transfer procedure and physician fee | Standard | Rare |
| Medications (estrogen, progesterone, often injectable) | Almost never | Always separate; can rival the procedure fee |
| Annual or ongoing embryo storage | Sometimes one year included | Often billed annually from retrieval |
| Additional PGT on remaining embryos | Never | Per-embryo plus lab fee |
The spread comes from what each quote counts. A clinic quoting $4,000 for a transfer cycle may be counting only the thaw and procedure, leaving monitoring and medications to land as separate bills totaling several thousand more. A clinic quoting $8,000 may include everything through the pregnancy test. Neither number is dishonest; both are incomplete until you ask which lines are inside.
Medication deserves its own warning. Luteal-phase support for a frozen cycle frequently includes intramuscular progesterone in oil, oral and vaginal estrogen, and sometimes GnRH agonist suppression. Pharmacy pricing for these drugs varies enormously between specialty pharmacies, and patients who compare pharmacies before filling report differences of hundreds to over a thousand dollars per cycle for identical prescriptions. No clinic controls this, but a good financial counselor will tell you which pharmacy their patients use and whether the clinic has negotiated pricing.
Bring these questions to the financial counselor in writing, and ask for the answers in writing too. Vague verbal answers here are the single largest source of billing disputes in fertility treatment.
That fourth question matters more than it looks. Storage fees are small individually, often a few hundred to around a thousand dollars per year depending on the program, but they accrue from the moment embryos are frozen, across however many months you take to decide on a next step. Patients who pause for six months between attempts regularly discover a storage invoice they had mentally written off.
Many American programs sell two-cycle and three-cycle packages, and some offer shared-risk or refund programs that return a large share of fees if no live birth occurs. Eligibility usually depends on age and ovarian reserve markers, and the fine print defines "cycle" in ways that matter: some packages count a frozen transfer as a separate cycle, others bundle a fixed number of transfers with a fixed number of retrievals.
Run the math against your own realistic expectations rather than against the brochure. If your diagnosis suggests a good chance of success in one or two attempts, a pay-per-cycle approach with transparent FET pricing may come out ahead. If you anticipate needing multiple retrievals, a package that includes frozen transfers can cap your downside. Neither structure is universally better, and the deciding variable is usually the same one this article keeps circling: how many transfers, at what marginal price, does the contract actually buy you?
Since the pretreatment window and the gap between attempts are where timelines slip, the clinics that handle this best are the ones with deliberate remote-coordination processes and flexible scheduling. Three programs illustrate different versions of that structure, and each publishes its own outcome data through the national reporting systems, so verify current figures directly with them.
HRC Fertility operates multiple locations across California, which matters for scheduling resilience: if monitoring capacity is tight at one site, patients can often be accommodated at another within the same practice. For patients who need a stimulation start date to align with a fixed travel window, that internal flexibility reduces the odds of a delayed cycle.
New Hope Fertility Center in Manhattan has a long history of treating international patients, including those pursuing mild-stimulation protocols that involve fewer injection days. Mild protocols change the cost structure in an interesting way: medication spending drops substantially per cycle, while the probability of needing more than one retrieval rises for some patient profiles. Whether that trade suits you depends on your reserve markers and your tolerance for a longer overall timeline in exchange for a lower-cost, lower-burden per-cycle experience.
San Diego Fertility Center, established in 1989, runs a high-volume laboratory and regularly coordinates with outside physicians for the pretreatment phase, which is the arrangement international patients need most. Confirming that a clinic will supervise suppression or thyroid correction remotely through your local provider, with clear handoff documentation, is worth more than any single line on a price sheet.
These three are examples of structural fit, and the same evaluation logic applies anywhere: ask who manages your care during the weeks you are not physically present, and what that management costs.
Patterns repeat across patients who end up spending more than planned, and nearly all of them trace back to the two windows described above.
Compress everything above into a document you can send to a clinic's financial office. A serious program will answer all of it within a week; hesitation on these items tells you something too.
The printed average cost of IVF in the United States is a useful starting number and a poor planning number. Treatment cost is really the sum of the quote plus the calendar: the weeks of preparation that determine how many eggs a retrieval yields, and the pricing of every attempt after the first. Patients who interrogate those two items before signing, who get the FET structure and the remote-coordination terms in writing, and who compare pharmacy pricing before filling, routinely finish treatment with both more money and more time in hand than patients who negotiated only the headline price.
Cost figures in this article reflect commonly cited industry ranges for self-pay patients and vary by clinic, region, protocol, and pharmacy. Verify all pricing against each clinic's official published fee schedule, and verify clinic-specific outcomes through the CDC's Assisted Reproductive Technology reporting system and the clinics' own published data. This article is informational and does not replace consultation with a reproductive endocrinologist.
